Your genes are the same, whether in a test tube or inside your body. But the very act of removing them makes them a patentable invention, according to Australia’s Federal Court. Today, it handed down the country’s first decision on gene patenting.
By isolating a human gene from the body, even assuming it has “precisely the same chemical composition and structure as that found in the cells of some human beings”, an “artificial state of affairs” had been created, making the gene patentable material.
The ruling relates specifically to a , which are associated with an increased risk of breast and ovarian cancer. Tests for the genes can help determine the likelihood of someone developing the diseases at a later date. The patent, which was filed by Myriad Genetics in 1994, in principle gives the company exclusive rights to perform such tests in Australia. The firm’s patent was later contested by Cancer Voices Australia, a patient advocacy group, and Yvonne D’Arcy, who had previously had breast cancer.
Today’s decision has raised eyebrows. “It is difficult to think of the circumstances where an artificially created state of affairs would not exist whenever there is some form of human intervention,” says at the University of Tasmania, Australia, who specialises in law and human genetics.
Advertisement
She says the counter view is that isolating a gene from the body is similar to snapping a leaf from a tree: since the process is so commonplace, it doesn’t represent a substantially artificial state of affairs.
It is likely the applicants will appeal, , principal lawyer at Maurice Blackburn who represented Cancer Voices Australia, told Â鶹´«Ã½. “We and our client remain very committed in our opposition to gene patents,” she says.
The ruling comes before the US Supreme Court will hear an appeal over a very similar case between Myriad and the American Civil Liberties Union, which was awarded to Myriad in a lower court.
“Since patent criteria are similar, a decision in one jurisdiction can indicate what might happen in another,” says from the Duke Institute for Genome Sciences and Policy in Durham, North Carolina.
In Australia, Myriad licensed its BRCA1 patents to . However, when Genetic Technologies in 2008, a public outcry forced the company to .
“But there was – and still is – nothing in the law to prevent such an [enforcement] being made in the future,” says , an oncologist and CEO of Cancer Council Australia, who is calling for the law to be changed to rule out gene patents.
In the US, where Myriad has enforced its patent, tests for BRCA1 must all be done by that company .
For Australian genetic researchers, the patent’s effect will be mitigated because in 2012 the country’s parliament introduced an ““, whereby researchers investigating a patent’s subject matter, or related areas, cannot be found to infringe the patent.
Topics:
